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The formation of Intracardiac thrombi is rare in the absence of structural heart disease or atrial ﬁbrillation. We describe a case
of spontaneous right atrial thrombus formation that occurred in a patient with a hypercoagulable condition who had been sub
optimally anticoagulated.
1.Introduction
Sickle cell disease (SCD) is an inherited autosomal recessive
disorder characterized by the formation of haemoglobin S
(HbS) resulting from the amino acid substitution of glu-
tamate to valine on the beta chain of haemoglobin. The vas-
oocclusive and haemolytic complications of this disease are
well known however it is worth noting that there are clinical
manifestations of this hypercoagulable disease such as large
vessel thrombosis, and in rare cases, intracardiac thrombus.
We report a case of spontaneous right atrial thrombus
formation in a patient with sickle cell disease who had been
suboptimally anticoagulated.
2.CaseReport
A 52-year-old man with haemoglobin SC disease, a previous
surgical splenectomy 26 years prior, following a crisis,
and pulmonary arterial hypertension secondary to chronic
thromboembolic disease, presented with acute dyspnoea
and pleuritic chest pain. Four days earlier, he had run out
of warfarin and had neglected to renew his prescription.
His admission ECG showed anterolateral ST depression
and his troponin I measured 16μg/L. The international
normalized ratio was 1.1. He was hypotensive with a systolic
bloodpressureof95mmHgandtachycardicwithapulserate
of 120 per minute with low oxygen saturations at 88%. His
hemoglobin concentration was measured at 9.0g/dL.
An urgent computed tomographic pulmonary angiogra-
phy did not demonstrate fresh pulmonary emboli. Exchange
bloodtransfusionwasundertakenbecauseoflowoxygensat-
urations the day after admission but this did not improve
the situation. He continued to complain of chest pains and
subsequently had an episode of collapse two days later with
further T wave and ST ECG changes.
Transthoracic echocardiography (TTE) demonstrated a
large thrombus within the right atrium (Figure 1(a)). This
was moving freely into the right ventricle, the pulmonary
artery, and the inferior vena cava. There was no clinical ev-
idence of deep vein thrombosis.
The patient received thrombolysis with an initial bolus
then infusion of alteplase. Repeat TTE 21 hours later dem-
onstrated disappearance of the thrombus (Figure 1(b)). The
patient was restarted on warfarin and recovered.
3. Discussion
Spontaneous right atrial thrombus formation is rare in
patients without structural right heart disease or atrial ﬁ-
brillation. Mobile right-sided thrombi, in particular, are2 Case Reports in Medicine
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Figure 1: (a) shows “snake-like” thrombus within right atrium. (b) shows dissolution of thrombus post ﬁbrinolytic agent.
thought to be a severe form of venous thromboembolism,
arising from deep vein thrombosis [1]. These can produce
emboli at any time and are associated with a high mortality
rate greater than 40% [2]. Immediate treatment is therefore
imperative.
Right heart thrombi have been identiﬁed in diseases of
hypercoagulability such as protein C and S deﬁciency [3],
Behcets disease [4, 5], and inﬂammatory bowel disease [6]. It
remains a very rare presentation of sickle cell disease but we
have found one reported case in literature [7]. In an autopsy
case series of fourteen patients with sickle cell disease that
died within a 15-year period, right atrial thrombosis was
found in one patient who had presented ante mortem with
an acute chest syndrome [8].
SCD predisposes to hypercoagulability due to abnormal
activation of the ﬁbrinolytic system by abnormal sickle cells
which activate the prothrombinase complex resulting in pro-
ductionofhighplasmalevelsofthrombin.Depletionofanti-
coagulation factors, increased tissue factor expression, and
chronic platelet activation also play an important role [9].
Splenectomy in haematological diseases such as Beta tha-
lassaemia intermedia and SCD, have been thought to further
contribute to this observed hypercoagulable state and subse-
quent thromboembolic complications, due to the procoagu-
lant activity of a high number of circulating damaged RBC,
thrombocytosis, and activation of the coagulation system
which occur [10, 11]. Unlike the Beta thalassaemias however,
there is currently little in terms of literature which shows this
directassociationbetweensicklecelldiseaseandsplenectomy
in particular [12].
Up to 30% of patients with SCD will develop pulmonary
arterial hypertension (PAH) and this is known to be associ-
ated with signiﬁcant morbidity and mortality. Several mech-
anisms are recognised in the pathogenesis of PAH which
include recurrent hemolysis, nitric oxide deﬁciency, vascular
bedremodeling,andchronichypoxaemia[13,14].Recurrent
thromboembolic disease is also thought to contribute and
undoubtedly some of such cases can be attributed to occult
thromboembolism caused by intracardiac thrombi.
Though SCD is a hypercoaguable state, the roles of anti-
coagulants have not been well deﬁned and larger controlled
trials are required to deﬁne their role [9]. As mentioned,
chronic pulmonary thromboembolism is a recognized asso-
ciation and in such cases it is generally acceptable to ad-
minister oral anticoagulant therapy and there is the sug-
gestion that low dose anticoagulation in these patients may
reverse some of the prothrombotic phenomena [15]. Our
patient was already on warfarin due to chronic small vessel
pulmonary thromboembolism but was Suboptimal from
noncompliance issues. Suboptimal anti-coagulation and the
risk of intracardiac thrombus formation have already been
described in other cases of high-risk patients for intracardiac
thrombi formation, such as cardiac surgery [16].
Theimportanceoftransthoracicechocardiogramasakey
simple, noninvasive, and rapid investigation for diagnosing
intracardiac thrombi is highlighted here. A retrospective
study by Chartier et al. of 38 patients with mobile right-
heartthrombialsounderlinestheusefulnessofTTEasaﬁrst-
line investigation [1] allowing rapid life-saving treatment to
be initiated. Felner et al. in a small study of patients with
clinically unsuspected right atrial thrombemboli, found that
TTE was instrumental in making a diagnosis and providing
information on the size, shape, mobility, and location of
subsequently demonstrated intracardiac thrombi in these
patients [17]. In more recent studies transoesophageal ech-
ocardiogram has been noted to be particularly invaluable
in the diagnosis of right-sided cardiac masses and where
available may be a preferred option with a high diagnostic
yield achievable [18, 19].
There is no clear consensus of the preferred treatment
option and until a randomized control trial is embarked on,
the debate will continue. Factors that have been considered
however include extent, size, shape, and mobility of the car-
diac thrombus, preexisting pulmonary embolism/deep veinCase Reports in Medicine 3
thrombosis, and cardiopulmonary reserve [3, 20]. Chartier’s
study did not delineate a statistical diﬀerence between
various treatment modalities and mortality; these included
surgical thrombectomy, intravenous thrombolysis, intra-
venous heparin, and percutaneous intervention. However it
is worth noting that in the European Cooperative Study, the
heparintreatedgroupregisteredahighmortalityrate[1,21].
In general, patients with intracardiac thrombi who present
with coexisting pulmonary embolism and/or hemodynamic
embarrassment seem to do better with thrombolytic therapy.
This represents a safe and eﬀective option with rapid reso-
lution of thrombus, improvement of hemodynamic status,
and echocardiographic parameters of acute right ventricular
overload [22]. Complication rates were also noted to be
infrequent [23].
Mortality in patients with intracardiac thrombi remains
high. Chartier et al. study found that a ﬁfth of their patients
diagnosed with right atrial thrombi died within 24 hours oﬀ
admission [1]. In a review by the European working group
of echocardiography, they observed that patients with Type
A thrombi (long, thin, extremely mobile thrombi which
resembled a worm or a snake), which is similar to what our
patient presented with, had early mortality (< or equal to 8
days) in excess of 42% and overall prognosis was generally
poor. The presence of pulmonary embolism on its own in
association with right heart thromboembolism was found
to be a poor prognostic indicator. This further emphasizes
the need for rapid diagnosis and emergency treatment to
prevent mortality [2].
4. Conclusion
Sickle cell disease as a hypercoaguable state is a rare risk
factor for intracardiac thrombus. A high index of suspicion
is therefore needed to make a diagnosis. TTE can provide
a rapid diagnosis of intracardiac thrombosis and inﬂu-
ence immediate life saving management. In this instance,
intravenous thrombolytic therapy oﬀered a safer and more
acceptable alternative to surgical removal of the thrombus.
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